Recombinant CCR2 (Plozalizumab Biosimilar) anticorps

N° du produit ABIN7488078

L’anticorps Mammalian Cells Monoclonal anti-CCR2 (Plozalizumab Biosimilar) a été validé pour ELISA. Il convient pour détecter CCR2 (Plozalizumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant CCR2 (Plozalizumab Biosimilar) anticorps (ABIN7488078)

Antigène: CCR2 (Plozalizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp CCR2 (Plozalizumab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-CCR2 (Plozalizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb

Attributs du produit: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur CCR2 (Plozalizumab Biosimilar)

Antigène: CCR2 (Plozalizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: MLN-1202,anti-CCR2,hu1D9
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation.

Numéro CAS: 1610761-46-0